Source: International Congress 2019 – Advances in COPD pharmacology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Blinova (Chelyabinsk, Russian Federation), G. Ignatova (Chelyabinsk, Russian Federation), I. Grebneva (Chelyabinsk, Russian Federation), O. Rodionova (Chelyabinsk, Russian Federation). Effect of 2-Year therapy with Roflumilast in severe systemic inflammation in COPD with metabolic syndrome. 2041

Member's Comments

No comment yet.

Related content which might interest you: Effects of infliximab on local and systemic inflammation in patients with COPD suffering from cachexia Source: Eur Respir J 2006; 28: Suppl. 50, 105s Year: 2006 Systemic inflammation in patients with COPD and anemia of chronic disease Source: International Congress 2019 – Airway diseases and blood cells Year: 2019 Effect of systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 624s Year: 2006 Endothelial dysfunction and systemic inflammation during acute exacerbations of COPD Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Metabolic syndrome in patients with COPD and their association with systemic inflammation Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Systemic inflammation in patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Principles of diuretic therapy of oedema syndrome in chronic obstructive pulmonary disease patients Source: Eur Respir J 2006; 28: Suppl. 50, 626s Year: 2006 Effects of infliximab on systemic features in patients with COPD suffering from cachexia Source: Eur Respir J 2006; 28: Suppl. 50, 105s Year: 2006 Influence of systemic inflammation and hypoxaemia on bone metabolism in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Systemic inflammation in patients with exacerbated chronic obstructive pulmonary disease (COPD): are anaemia of chronic disease and erythropoietin resistance the missing links? Source: Annual Congress 2007 - Pathophysiology and assessment of COPD Year: 2007 Rosuvastatin effects on systemic inflammation, oxidative stress and antioxidants in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – COPD diagnosis and management Year: 2016 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 Treating systemic effects of COPD Source: Annual Congress 2009 - Emerging trends in the therapy of COPD Year: 2009 Treating systemic effects of COPD Source: Annual Congress 2012 - PG9 Progress on the treatment of COPD Year: 2012 Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors Source: International Congress 2014 – Asthma and COPD management Year: 2014 Anabolic steroids in acute and chronic disease Source: ISSN=1025-448x, ISBN=1-904097-27-8, page=163 Year: 2003 Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Effect of statins on endothelial dysfunction in patients with chronic obstructive pulmonary disease and metabolic syndrome Source: International Congress 2014 – Mechanisms of COPD and inhalation injury Year: 2014 Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD Source: Eur Respir J 2005; 26: Suppl. 49, 721s Year: 2005